Format

Send to

Choose Destination
See comment in PubMed Commons below
J Card Fail. 2011 Dec;17(12):1051-8. doi: 10.1016/j.cardfail.2011.08.006. Epub 2011 Sep 9.

Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats.

Author information

1
Cardiovascular Division, Beth Israel Deaconess Med Center, Boston, MA 02215, USA.

Abstract

BACKGROUND:

Activated vitamin D analog, paricalcitol, has been shown to attenuate the development of cardiac hypertrophy in Dahl salt sensitive (DSS) rats. To determine whether an antihypertrophic effect is class specific, we tested if doxercalciferol (a pro-hormone vitamin D2 analog) could also attenuate the development of cardiac hypertrophy in DSS rats.

METHODS AND RESULTS:

Male DSS rats were fed a high salt (HS) diet for 6 weeks beginning at 6 weeks of age. Doxercalciferol was administered intraperitoneally at 150 ng, 3 times per week (Monday, Wednesday, Friday) for 6 weeks. Pathological and echocardiographic findings demonstrated that rats on HS diet with doxercalciferol administration had significant decrease in cardiac hypertrophy and improved cardiac function compared to the HS + vehicle. In addition, there was a significant decrease in plasma brain natriuretic peptide (BNP) level and tissue atrial natriuretic factor (ANF) mRNA level with doxercalciferol treatment. Doxercalciferol also significantly reduced the level of protein kinase C-α (PKCα) suggesting that PKC-mediated cardiac hypertrophy may be associated with vitamin D deficiency.

CONCLUSIONS:

Administration of doxercalciferol attenuated the development of HS diet induced cardiac hypertrophy and cardiac dysfunction in DSS rats.

PMID:
22123370
PMCID:
PMC3226953
DOI:
10.1016/j.cardfail.2011.08.006
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center